Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$79.48 USD

79.48
3,306,185

-2.33 (-2.85%)

Updated Aug 5, 2024 02:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top

Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.

    Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

    Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.

      Arpita Dutt headshot

      Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ

      The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.

        Arpita Dutt headshot

        Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback

        Merck's (MRK) news represents the latest setback in the pharma and biotech sector's quest to find a treatment for Alzheimer's.

          Lilly's Olumiant Gets Marketing Authorization in Europe

          Eli Lilly and Company (LLY) along with its partner Incyte Corporation (INCY) announced that the European Commission has granted marketing authorization to once-daily baricitinib in Europe.

            Arpita Dutt headshot

            Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi

            Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.

              Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)

              Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.

                AstraZeneca (AZN) Beats on Q4 Earnings but Misses on Sales

                AstraZeneca PLC (AZN) reported fourth-quarter 2016 core earnings of $1.21 per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 51 cents. Core earnings also rose 9% year over year.

                  Agilent (A) Announces Expanded Use of Diagnostic Assay

                  Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 28-8 22C3 pharmDx. This marks the company's effort to expand in the growing companion diagnostics market.

                    Allergan (AGN) Avycaz Label to Include New Phase III Data

                    Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.

                      Ironwood/Astellas Report Positive Phase III Data on Linzess

                      Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.

                        AstraZeneca's Symbicort Granted Pediatric Exclusivity by FDA

                        AstraZeneca (AZN) announced that the FDA has granted six months of pediatric exclusivity to its Symbicort inhalation aerosol.

                          Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose

                          Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).

                            Microsoft (MSFT) Beats on Q2 Earnings, Revenue Estimates

                            Microsoft Corporation (MSFT) reported second-quarter fiscal 2017 earnings of 83 cents per share, which comfortably surpassed the Zacks Consensus Estimate of 79 cents.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint

                              Key highlights this week include earnings reports from companies like Bristol-Myers (BMY) as well as the J&J-Actelion deal.

                                AstraZeneca Offers Update on Immuno-Oncology Program

                                AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

                                  Can AstraZeneca (AZN) Be a Solid Choice for Value Investors?

                                  Let's see if AstraZeneca (AZN) stock is a good choice for value-oriented investors right now from multiple angles.

                                    Arpita Dutt headshot

                                    The FDA Approved Fewer Drugs in 2016: Here's Why

                                    Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

                                      Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

                                        Arpita Dutt headshot

                                        Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

                                        Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

                                          Pfizer Ibrance sNDA Accepted by FDA under Priority Review

                                          Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

                                            Clovis Scales 52-Week High on Early FDA Nod for Rubraca

                                            Shares of Clovis Oncology (CLVS) touched a 52-week high after the company gained accelerated FDA nod for its advanced ovarian cancer drug, Rubraca.

                                              Ionis (IONS) Receives Milestone Payment from AstraZeneca

                                              Ionis (IONS) received $28 million from AstraZeneca (AZN) following the completion of IND-supporting studies and licensing of IONIS-KRAS-2.5.

                                                Alexion Slips to 52-Week Low as CEO, CFO Quit amid Probe

                                                Alexion's (ALXN) shares plunged after the company's board of directors announced new leadership appointments.

                                                  Biogen Presents Positive Early Data from Alzheimer's Study

                                                  Last week, Biogen Inc. (BIIB) presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.